James F. Howard, MD
Affiliations: | 1979- | Neurology | University of North Carolina, Chapel Hill, Chapel Hill, NC |
Area:
neuromuscular junction, myasthenia gravis, complement inhibitionWebsite:
https://www.med.unc.edu/neurology/directory/james-f-howard-jr-md/Google:
"James f Howard jr"Mean distance: 106866
Parents
Sign in to add mentor| Thomas Richards Johns | grad student | UVA School of Medicine | ||
| (resident in neurology) | ||||
| Charles Marcel Poser | grad student | University of Vermont College of Medicine | ||
| (medical student) | ||||
Children
Sign in to add trainee| Kathleen D. Kennelly, | post-doc | 1990-1992 | Mayo Clinic Jacksonville |
| Ratna Bhavaraju-Sanka | research scientist | 2007-2010 | University of Texas Health Science Center - San Antonio |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mantegazza R, O'Brien FL, Yountz M, et al. (2020) Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Annals of Clinical and Translational Neurology |
| Areson DG, Filer WG, Harris MG, et al. (2020) Accuracy of the Scratch Collapse Test for Carpal Tunnel Syndrome in Comparison With Electrodiagnostic Studies. Hand (New York, N.Y.). 1558944719895786 |
| Albazli K, Kaminski HJ, Howard JF. (2020) Complement Inhibitor Therapy for Myasthenia Gravis. Frontiers in Immunology. 11: 917 |
| Jacob S, Murai H, Utsugisawa K, et al. (2020) Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study. Therapeutic Advances in Neurological Disorders. 13: 1756286420911784 |
| Vissing J, Jacob S, Fujita KP, et al. (2020) 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. Journal of Neurology |
| Howard JF, Nowak RJ, Wolfe GI, et al. (2020) Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. Jama Neurology |
| Howard JF, Bril V, Burns TM, et al. (2019) Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology |
| Andersen H, Mantegazza R, Wang JJ, et al. (2019) Eculizumab improves fatigue in refractory generalized myasthenia gravis. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation |
| Clifford KM, Hobson-Webb LD, Benatar M, et al. (2018) Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle & Nerve |
| Li Y, Guptill JT, Russo MA, et al. (2018) Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients. Experimental Neurology |